Back to search

Finland· FI-REL-REL9360

Bezafibrat Generics

A bezafibrate product containing bezafibrate, registered in Finland by Generics (UK) Limited. The same ATC class is registered in 10 of our 19 countries.

ATC C10AB02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedBezafibrat GenericsATCC10AB02REGISTER NO.FI-REL-REL9360PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Bezafibrate is registered in 10 of 19 countries.

Countries holding a registration under ATC C10AB02 (bezafibrate), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 6 of them publish a price we can compare per daily dose

Bezafibrate · ATC C10AB02

10 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Italyprice
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bezafibrate costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), the median price runs from $0.29 in France to $1.19 in Switzerland — a ×4.1 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Bezafibrate · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.19
  • IT Italy$0.44
  • FR France$0.29
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Bezafibrate
Manufacturer
Generics (UK) Limited
Country
Finland (FI)
ATC code
C10AB02
ATC class
Bezafibrate
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Bezafibrate in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bezafibrate products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Bezalip Retard, Bezastad
  • Belgium · Cedur, Eulitop
  • Cyprus · Lacromid, Zafibral
  • Germany · Bezafibrat Al, Bezafibrat Retard Al
  • Spain · Eulitop, Eulitop Retard
  • France · Befizal, Befizal L.P.
  • United Kingdom (Northern Ireland) · Bezafibrate, Bezafibrate Noumed Life Sciences
  • Hungary · Bezalip
  • Italy · Bezalip
  • Luxembourg · Cedur, Eulitop
  • Netherlands · Bezafibrate Aurobindo
  • Portugal · Bezalip, Bezalip Retard
  • Romania · Bezafibrat Arena
  • Sweden · Bezalip, Bezalip Retard

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ad789673-3ea0-406c-9b76-2bf2167ee478
GET /v1/drugs/ad789673-3ea0-406c-9b76-2bf2167ee478?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.6",
  "form": "depottabletti",
  "route": null,
  "ddd_unit": "g",
  "strength": "400 mg",
  "atc_label": "betsafibraatti",
  "ma_number": "12770",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL9360",
  "authorised_at": "1998-04-06"
}

See everything about bezafibrate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.